Carregant...
Modulation of NKG2D-ligand cell surface expression enhances immune cell therapy of cancer
A variety of immune cell therapies proposed for use in the treatment of cancer, including both autologus cells (Lymphokine Activated Killer, Cytokine Induced Killer) or cell lines (TALL-104, NK-92), rely on recognition of NKG2D ligands on malignant cells for targeting. These ligands, such as MICA an...
Guardat en:
| Autors principals: | , , , |
|---|---|
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
2011
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3073622/ https://ncbi.nlm.nih.gov/pubmed/21389869 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CJI.0b013e31820e1b0d |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|